ClearVue Technologies (CPV) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
27 Mar, 2026Executive summary
Revenue increased 528% year-over-year to $249,925, with net loss after tax improving by 7% to $11.58 million.
Major geographic expansion into the Middle East, China, New Zealand, and Africa, with new manufacturing and distribution agreements.
Product suite expanded to include solar spandrel, cladding, skylights, and balustrade, enhancing market credibility and deployment options.
Strategic partnerships and licensing agreements secured with LandVac, Maxblue, Viridian Glass, and Alutec.
Leadership transition with new Chairperson, CEO, and board members appointed in July-August 2025.
Financial highlights
Revenue from contracts with customers: $249,925 (up from $39,811 in FY24).
Net loss after tax: $11,584,706 (improved from $12,491,037 in FY24).
EBITDA: $(10,240,209), EBIT: $(11,551,571).
Basic loss per share: (4.5) cents (FY24: (5.4) cents).
Cash and cash equivalents at year-end: $3,591,254.
No dividends declared or paid.
Outlook and guidance
Focus on global commercialisation, leveraging new partnerships and expanded product suite.
Continued investment in R&D and innovation pipeline, supported by tax incentives and government support.
Restructuring in North America and cost-saving initiatives expected to deliver $3.4m in annualised savings.
Ongoing review of company structure and strategic growth options by Kidder Williams.
Latest events from ClearVue Technologies
- Commercial deployments and certifications advanced, while quarter-end cash runway stood at 1.3 quarters.CPV
Q1 2027 - Solar façades target a USD 183B serviceable market through an asset-light model.CPV
Investor presentation - Revenue declined and losses persisted, but global project wins and certifications position for growth.CPV
H2 2026 - Surpassed cost reduction targets, advanced BIPV innovation, and expanded global partnerships.CPV
Investor presentation - Cost reductions, certifications, and global pipeline growth drive commercial momentum.CPV
Investor update - Commercialisation accelerated with global sales, expanded product range, and increased funding.CPV
H2 2024 - Net loss narrowed as restructuring and Gen3 rollout set stage for future growth.CPV
H1 2026 - Licensee growth, product advances, and cost cuts support commercialisation and funding.CPV
Q2 2026 TU - Operational progress and new certifications set to drive revenue growth and market expansion.CPV
Status update